Stock Alert: Cns (CNSP) Up 5.71% in Pre-Market Hours for June 23

Equities Staff  |

Cns Pharmaceuticals Inc (NASDAQ:CNSP) has already climbed $0.016 in early trading Thursday.

After closing the previous trading session at $0.28, Cns has moved 5.71% higher ahead of market open.

The company has risen 2.68% over the last 5 days.

Today could shape up to be an attractive day for Cns investors.

For technical charts, analysis, and more on Cns Pharmaceuticals Inc visit the company profile.

Pre-market prices and movements as of 07:32:22 est.

About Cns Pharmaceuticals Inc

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%.

To get more information on Cns Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Cns Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content